-
E-mail
marklee@hankosci.com
-
Phone
15800598580
-
Address
Kaixin Business Park, No. 1325 Hengnan Road, Minhang District, Shanghai
Shanghai Haokuo Scientific Equipment Co., Ltd
One click electric shock, quadruple transformation: How MaxCyte clears obstacles for AML universal CAR-T therapy?
Date: 2025-11-17Read: 0
In the world of cell therapy, acute myeloid leukemia (AML) has always been a tough nut to crack. Especially for patients with relapsed or refractory AML, the path of conventional chemotherapy is becoming increasingly narrow, while the hope of hope - hematopoietic stem cell transplantation (HSCT) - requires patients to first enter a "remission" state.
It's like a vicious cycle: if you want to survive, you have to go on the "transplant" ship, but the ticket to get on board is "relief", and the "chemotherapy" card in your hand cannot achieve this effect.So everyone turned their attention to CAR-T, the "cell killer" who has made great achievements in other fields of hematological oncology.
01. Ideal is Full: Creating a "Universal" Love Killer
Directly using the patient's own T cells (autologous CAR-T) to treat rrAML has not been effective. The reason is simple: after multiple rounds of chemotherapy, the T cells in the patient's body have become "exhausted soldiers" and their combat effectiveness has been greatly reduced.
So, a better idea is to use T cells from healthy donors to create a "ready to use" universal CAR-T (allogeneic CAR-T). It's like calling in a well-equipped and energetic special forces unit directly from the reserve.
But this' mercenary 'has two fatal problems:
(1) Friend or foe (graft-versus-host disease, GvHD): It may attack the patient's healthy tissue, as it is not "original". It must knock out its native T cell receptor (TCR), which is equivalent to dismantling its "home navigation system" and preventing it from running around.
(2) Accidentally injured by friendly forces (immune rejection): The patient's own immune system will regard this foreign unit as an invader and launch a collective attack. It is necessary to knock out its identity identifier - HLA-I molecules, which is equivalent to putting a "invisibility cloak" on it, making it invisible to the patient's "defense system".
Okay, we have the blueprint: we need to perform a 'magic modification' on healthy T cells - knocking out TCR, knocking out HLA-I, and then knocking in a CD33-CAR that can recognize AML cells.
02. Reality is tough: How to accomplish three things in one step?
It is a huge engineering challenge to efficiently insert so many "modification instructions" (two CRISPR RNPs for gene knockout, one Sleeping Beauty transposase mRNA for knock in, and one lentiviral DNA carrying CAR gene) into delicate T cells at once. The traditional virus vector method has complex processes, high costs, long cycles, and potential security risks. Is there a way to accurately deliver this' genetically modified luxury gift package 'to cells like pressing a switch at once?
03. MaxCyte Debuts: From 'Impossible' to 'One Click Solution'
This is precisely the core value demonstrated by researchers from the University of Navarre in this application report. They use MaxCyte GTx ™ The flow cytometry transfection platform solves the problem of "one-step delivery". It uses a non viral approach to successfully introduce four different functional biomolecules, CRISPR RNP, Sleeping Beauty transposase mRNA, and CD33-CAR transposon mini circle DNA, into T cells in a single electrocution operation.
This operation can be described as "fast, accurate, and ruthless", and its value is reflected in:
• Simple and efficient: The core steps of genetic engineering have been simplified into a single electroporation, greatly reducing preparation time. The data shows that after modification, an average of 32.4% of CD33-CAR positive cells can be obtained, and over 69% of cells have successfully achieved dual gene knockout.
Cell friendly: This "physical breakthrough" approach may seem rough, but it is actually gentle. The modified CAR-T cells still maintain strong proliferation ability and ideal cell phenotype, without being severely damaged by this wave of "electroconvulsive therapy", and their combat effectiveness remains unchanged.
• Powerful function: Whether it is in vitro cytotoxicity experiments or in vivo anti-tumor activity tests in mouse models, these "one-step" CD33 AlloCART cells have shown consistent and powerful tumor killing effects as cells prepared by traditional methods.
Seamless amplification: The most crucial aspect is that this technology possessesgoodScalability (scalability). Whether it is a small-scale trial scale of 2x10 ⁶ cells or a clinically relevant production scale of 5x10 ⁷ cells, the efficiency, phenotype, and function of cell modification are highly consistent. This means that the path for this technology to move from the laboratory to clinical practice and achieve commercial production is smooth. Ultimately, starting cells of 5x10 ⁷ can yield over 3x10 ⁸ of purified CAR-T products.
04. Summary: Choose MaxCyte, choose efficiency
Faced with the stubborn enemy of rrAML, scientists have designed a precise "universal" CAR-T celltherapyMaxCyte's electroporation technology has become a key "smart manufacturing platform" for forging this divine weapon. It solves the complex cell engineering delivery problem with a non viral, one-step, scalable approach, bringing the "ready to use" CAR-T therapy one step closer to reality.
This is not only a validation of a technology, but also a new light of hope for AML patients struggling in difficulties.
*This article is reproduced from the WeChat official account of "Toppaolo" by Yuwen Mathematic
▍Regarding MaxCyte:
MaxCyte was founded in 1999 and is headquartered in Maryland, USA. It is a provider of cell engineering electroporation technology solutions. Utilize its ExPERT ™ The electroporation platform can efficiently and stably achieve engineering processing of large-scale cells, meeting the full stage of cell transfection needs from early research, clinical development to commercial production. It widely serves fields such as antibody protein expression, vaccine development, gene editing, and cell and gene therapy. ——As the general agent of MaxCyte in the southern region of China, Shanghai Haoxuan will provide you with professional solutions and technical support that meet your cell transfection requirements at different stages of research and development, clinical practice, and commercial production.
▍Regarding Shanghai Haokuan:
Shanghai Haokuo Scientific Equipment Co., Ltd. was established in 2019 and is headquartered in Shanghai. It is a professional service provider of laboratory equipment/consumables and analytical instruments. The company is committed to providing high-tech professional equipment and technical consulting services to customers in the fields of biology, medicine, physical property testing, chemical analysis, food, industrial production, and other related fields at home and abroad.